A conformation of the neurohypophyseal hormone oxytocin in solution is proposed. The structure possesses, in addition to the (-turn comprised of the sequence -L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-in the ring component of the hormonal molecule, a second ,8-turn involving the C-terminal oxytocin sequence, -L-cysteinyl-L-prolyl-L-leucylglycinamide. The resulting oxytocin structure places the bulky side chains of the leucine and isoleucine residues, as well as the cyclic moiety of the proline residue, at corners of the two i3-turns. A critical role is played by the asparagine residue: its peptide N-H participates in the formation of the hydrogen-bonded cyclic structure of the (3-turn in the ring component of oxytocin and its peptide C-O can be hydrogen-bonded to the N-H of tyrosine, while its side chain C=-O stabilizes the second /-turn by forming a hydrogen bond with the N-H of the leucine residue, which is part of the end peptide of the second (-turn. This conformational assignment of oxytocin is consistent with hydrogendeuterium exchange studies, with plots of temperature dependence of peptide proton chemical shifts, and with the coupling constants for the NH-CH dihedral angles.
Utilizing the proton nuclear magnetic resonance assignments of oxytocin by Johnson, Schwartz, and Walter (1), Urry et al. (2) have derived a secondary structure of the ring component of this hormonal peptide. The ring conformation is characterized as a cross (3-structure involving the sequence -tyrosyl-isoleucyl-glutaminyl-asparaginyl-, with the hydrogenbonded ring being closed by the N-H of asparagine and the C=O of tyrosine.
To complete the backbone conformation of oxytocin, we now propose a second (-turn, comprised of the sequence -cysteinyl-prolyl-leucyl-glycyl-, and utilizing the C=O of the cysteine residue in position 6 and the N-H of the glycine residue to close the hydrogen-bonded ring of the (-turn (see Fig. la and its schematic drawing Fig. lb) . The orientation of the peptide moiety that constitutes the end of both (3-turns is in agreement with the x-ray crystallographic data on ferrichrome-A (3) and the presence of similar conformations in lysozyme (4) , that is, with the N-terminus being on the bottom left and the gross feature of the (-turn being that of a D, the end peptide C=O being directed toward the observer (Fig. la,b) . This is the end peptide configuration commonly observed (3, 4) As may be seen in Fig. 2 , certain of the constituent amino acids of oxytocin are engaged primarily in stabilizing the conformation of the polypeptide backbone, while others contribute primarily to filling in the steric, electrostatic, and hydrophobic details comprising the topological features of the molecule. Thus, in addition to the importance of the cystine residue in completing the disulfide-containing ring component of oxytocin as assigned earlier (8, 9) , the asparagine residue is outstanding. It contributes both its peptide N-H and C=O to hydrogen bond formation within the cross (-structure of the cyclic moiety of oxytocin and its sidechain C==O to hydrogen bonding with the N-H of the leucine residue, which comprises part of the end peptide of the second (-turn. Also asparagine (2), the aromatic side chain seems not to be involved in intramolecular interactions (5) . The tyrosyl a-f proton-proton coupling constants are unequal in (CD3)2S0-D20, about 11 and 3 Hz, which places the hydroxybenzyl group either 3000 or, more likely, 1800 relative to the CO-N bond of tyrosine (10) . The cysteine residue in position 6 contributes its C=O to the closing of the second fl-turn, where the N-H of glycine is its counterpart. The side chains of four amino acids-isoleucine, glutamine, lproline, and leucine in positions 3, 4, 7, and 8, respectively-are located at corner positions of the f-turns, in which their side chains will minimally interact with the remainder of the molecule.
The above discussion, therefore, represents a proposal for major aspects of the overall conformation of oxytocin. It provides a basis with which to critically discuss biological activity and to probe details of receptor sites. Furthermore, the conformation suggests interesting specific derivatives that are not among the host of analogues already made. We are now entering an exciting period in which solution conformations of polypeptide hormones and antibiotics can be obtained. This capacity, together with that of peptide synthesis, provides optimism for correlating conformation with activity and perhaps for tailoring of biological molecules for enhanced activity and specificity. In addition, however, it should be appreciated that as general rules emerge for conformational features exceptions or modifications inevitably will follow. For example, the experimental evidence indicates that the orientation of an end peptide of a fl-turn for an L-L sequence (3, 4) is as depicted in Fig. 2 , yet it may be found that specific residues alter that generalization. This may be of particular interest in the case of neurohypophyseal hormones, and specifically in the case of oxytocin. The underside of the cross f-ring component is relatively featureless. No prominent chemical points of identification are found on this side, the single exception being the i=0 or the N-H of the end peptide moiety.
The capacity to shift from a hydrogen acceptor in a hydrogenbonding situation to a hydrogen donor on an otherwise plain area of the molecule, that is, to change the orientation of the end peptide, could provide a powerful discriminating feature for interacting at receptor sites. This and other aspects of the molecule are presently under investigation.
